Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

[Inverted Variant of Urothelial Carcinoma of the Urinary Bladder : A Case Report].

Authors:
Naoki Hirabayashi Osamu Nishizawa Noriyasu Kobayashi Meguru Ikeyama Hisanori Matoba Jun Nakayama

Hinyokika Kiyo 2019 Nov;65(11):463-467

The Department of Molecular Pathology, Shinshu University School of Medicine.

A 69-year-old male complained of gross hematuria. Cystoscopy revealed a papillary pedunculated tumor. The tumor was approximately 4 cm in length, and mimicked an inverted papilloma with a small stalk and smooth surface, located on the bladder trigone. Transurethral resection of the bladder tumor was performed, and the tumor was resected en bloc. Histopathological examination revealed thick and irregular epithelial cords. Immunohistochemically, Ki-67 labeling index was 5%, p40 and CK7 were positive, and CK20 was negative. Then, this tumor was diagnosed as inverted variant of urothelial carcinoma. Even when gross appearance is compatible with inverted papilloma, pathological and immunohistochemical examinations are essential for accurate diagnosis of inverted bladder tumor. No recurrence was observed by cystoscopy 13 months after the resection.

Download full-text PDF

 Source
http://dx.doi.org/10.14989/ActaUrolJap_65_11_463DOI Listing
November 2019

Publication Analysis

Top Keywords

variant urothelial
8
urothelial carcinoma
8
bladder tumor
8
inverted papilloma
8
tumor
6
months resection
4
examination revealed
4
ki-67 labeling
4
immunohistochemically ki-67
4
cords immunohistochemically
4
epithelial cords
4
irregular epithelial
4
thick irregular
4
revealed thick
4
resected bloc
4
histopathological examination
4
bloc histopathological
4
p40 ck7
4
[inverted variant
4
performed tumor
4

Keyword Occurance

Similar Publications

Diagnostic Value of the Vesical Imaging-Reporting and Data System in Bladder Urothelial Carcinoma with Variant Histology.

Authors:
Yuki Arita Soichiro Yoshida Keisuke Shigeta Thomas C Kwee Hiromi Edo Naoko Okawara Masahiro Hashimoto Ryota Ishii Ryo Ueda Shuji Mikami Motohiro Fujiwara Yuma Waseda Eiji Kikuchi Yasuhisa Fujii Masahiro Jinzaki

Eur Urol Oncol 2022 Aug 3. Epub 2022 Aug 3.

Department of Radiology, Keio University School of Medicine, Tokyo, Japan.

The value of the Vesicle Imaging-Reporting and Data System (VI-RADS) in the diagnosis of muscle-invasive bladder cancer (MIBC) for urothelial carcinoma with variant histology (VUC) remains unknown. We retrospectively evaluated 360 consecutive patients with bladder cancer (255 pure urothelial carcinoma [PUC] and 69 VUC) who underwent multiparametric magnetic resonance imaging between 2011 and 2019. VI-RADS scores assigned by four readers were significantly higher for the VUC group than for the PUC group (p < 0. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma.

Authors:
Nishita Tripathi Yeonjung Jo Abhishek Tripathi Nicolas Sayegh Haoran Li Roberto Nussenzveig Benjamin Haaland Vinay M Thomas Sumati Gupta Benjamin L Maughan Umang Swami Sumanta K Pal Petros Grivas Neeraj Agarwal Deepika Sirohi

Urol Oncol 2022 Jul 30. Epub 2022 Jul 30.

Department of Pathology, Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT. Electronic address:

Background: Urothelial carcinoma with squamous differentiation (UCS) is the most common variant differentiation of urothelial carcinoma (UC). Although treatment is usually similar to pure UC, there is paucity of data regarding its genomic landscape and putative molecular drivers. In this study, we compared the mutational profile of tumors with UCS and UC histology. Read More

View Article and Full-Text PDF
July 2022
Similar Publications

Whole-exome sequencing identified mutational profiles of urothelial carcinoma post kidney transplantation.

Authors:
Lee-Moay Lim Wen-Yu Chung Daw-Yang Hwang Chih-Chuan Yu Hung-Lung Ke Peir-In Liang Ting-Wei Lin Siao Muk Cheng A-Mei Huang Hung-Tien Kuo

J Transl Med 2022 07 21;20(1):324. Epub 2022 Jul 21.

Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Kidney transplantation is a lifesaving option for patients with end-stage kidney disease. In Taiwan, urothelial carcinoma (UC) is the most common de novo cancer after kidney transplantation (KT). UC has a greater degree of molecular heterogeneity than do other solid tumors. Read More

View Article and Full-Text PDF
July 2022
Similar Publications

Overview of histologic variants of urothelial carcinoma: current trends and narrative review on treatment outcomes.

Authors:
Olisaemeka Ogbue Abdo Haddad Nima Almassi James Lapinski Hamed Daw

Transl Androl Urol 2022 Jun;11(6):877-901

Department of Hematology/Oncology, Cleveland Clinic Cancer Center, Cleveland, OH, USA.

Background And Objective: The histologic variants of urothelial carcinoma (UC) are tumors arising from within the urothelium in which some component of the tumor morphology is other than urothelial. They are underdiagnosed, aggressive and have varying pathologic response rates to systemic chemotherapy. There are no consensus guidelines on the use of systemic chemotherapy in variant histology (VH) of UC. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.

Authors:
Ahmet Murat Aydin Salim K Cheriyan Richard Reich Ali Hajiran Charles C Peyton Logan Zemp Alice Yu Roger Li Michael A Poch Philippe E Spiess Rohit Jain Jingsong Zhang Wade J Sexton Scott M Gilbert

Urol Oncol 2022 Jul 7. Epub 2022 Jul 7.

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Purpose: Because the optimal number of cycles of neoadjuvant gemcitabine and cisplatin chemotherapy (GC) is unclear, we aimed to compare disease response and survival outcomes of patients receiving either 3 or 4 cycles of neoadjuvant GC for muscle-invasive bladder cancer (MIBC).

Methods: A total of 166 patients who were treated with neoadjuvant GC and radical cystectomy for clinical stage T2-4N0M0 were identified. Response and effectiveness of different cycle counts were assessed using downstaging (complete pathologic and partial pathologic response), cancer-specific survival (CSS), and overall survival (OS). Read More

View Article and Full-Text PDF
July 2022
Similar Publications
}